Από την εκπομπή ΤΟP STORY στο CAPITAL TV στις 12 ΙΟΥΛΙΟΥ 2019
The aim of the present study was to investigate the effect of a micronized formulation of trans‑resveratrol in humans with non‑alcoholic fatty liver disease (NAFLD). Trans‑Resveratrol has been used in the form of micronized formulation, which is better absorbed, has strong antioxidants effects, is more effective than plain resveratrol formulations and is circulated on the market as a food supplement. Resveratrol (3,5,4’‑trihydroxy‑trans‑stilbene) is a stilbenoid and a phytoalexin produced by several plants. NAFLD is an increasing clinical problem involving the liver for which effective treatments are required. The present study was based on two patient groups. The study, which commenced on April 2013 and finished on April 2015, included 44 patients, aged 29‑70 years, with an average weight of 84.6 kg (n=22 per group; 28 men and 16 women) who were randomly assigned to groups and given 50 mg Evelor capsule (n=22) and 200 mg Evelor H tablet (n=22) correspondingly on a daily basis. The patients were followed up for 6 months. Quantity fat measurements, with ultrasound on the liver and kidney, were carried out. There was an initial measurement (time 1) and one after six months (time 2). The study results showed the effects of Trans‑resveratrol micronized formulation in reducing the liver fat, as well as decreasing hepatic enzymes, serum glutamate pyruvic transaminase (SGPT) and gamma‑glutamyl transpeptidase (g‑GT) and insulin resistance. At the end of the study, the statistical analysis showed a statistically significant reduction on the liver fat. These data demonstrate that use of Trans‑resveratrol micronized formulation improves features of NAFLD, and prevents liver damage. Thus, Trans‑resveratrol micronized formulation can be a new treatment method for NAFLD.
Check the publication directly on Spandidos Publications website